Form D · Biotechnology
Sethera Therapeutics, Inc
Salt Lake City, UT · CIK 0002042692
Offering snapshot reported Oct 30, 2024 · SEC filing
- Reported sold
- $1.95M Offering amount: $3M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2024 | Initial | $1,949,463 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528211
Source: Form D, filed Oct 30, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vahe Bandarian | Director, Executive |
| Karsten Eastman | Director, Executive |
| Yakov Kogan | Executive |
| Cynthia Tsai | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
48 South Rio Grande Street
Salt Lake City, UT, 84101
Salt Lake City, UT, 84101